Gálvez-Valdovinos R, Hernández-López R, López-Ambriz G, Ramme-Cruzat C

Language: Spanish
References: 16
Page: 635-640
PDF size: 589.00 Kb.

ABSTRACT

Background: In 2010, Health Canada, the equivalent to the FDA, reported that the risk of uterine perforation caused by levonorgestrel intrauterine device (IUD) is very serious, warning that its use had increased the number of uterine perforation.
Clinical case: A 33 years old patient in who was placed three years before a levonorgestrel IUD; She presented evolution of 10 days with pain in hypogastric and both flanks and chronic constipation of two years; in exploration: moderate abdominal distention, IUD strings were not visible in uterine cervix. With translocated IUD diagnosis, a tomography was performed, finding IUD in abdominal cavity and ureter pyelocalyceal bilateral ectasia; preoperative plasma concentration of levonorgestrel 5.1 nmol/L, leukocytosis of 11,000 cells/mm³, and 20-30 erythrocytes in urine exam. Laparoscopic resection of omentum attached to IUD translocated was performed. One month after surgery plasma levonorgestrel in 0.3 nmol/L, normal urinalysis and hematic cytometry and resolution of the urinary tract ectasia.
Conclusions: devices translocated with levonorgestrel, must be removed because the inflammatory reaction caused and the perforation of hollow viscera likelihood, with possibility to produce digestive tract and urinary tract ectasia by its pharmacologic action on smooth muscle.

REFERENCES

1. Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention. U.S. Selected Practice Recommendations for Contraceptive Use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use. 2nd edition. MMWR Recomm Rep. 2013; 62 (RR-05):1–60.

2. Caliskan E, Ozturk N, Dilbaz BO, Dilbaz S. Analysis of risk factors associated with uterine perforation by intrauterine devices. Europ J Contracept Reprod Health Care 2003;8:150-155.

3. Gill RS, Mok D, Hudson M, Shi X, Birch DW, Karmali S. Laparoscopic removal of an intra-abdominal intrauterine device: case and systematic review. Contraception 2012;85:15-18.

4. Juárez AA, Romero HS, Motta-ME. Perforación uterina y de rectisigmoides por dispositivo intrauterino: presentación de un caso y revisión de la literatura. Gac Med Mex 2003;139:73-75.

5. Tedeschi A, Di Mezza G, D’Amico O, Ermann A, Montone L, Siciliano M, Cobellis G. A case of pelvic actinomycosis presenting as cutaneous fistula: case report. Europ J Obstet Gynecol Reprod Biol 2003;108:103-105.

6. Miranda L, Settembre A, Capasso P, Cuccurullo D, Pisaniello D, Corcione F. Laparoscopic removal of an intraperitoneal translocated intrauterine contraceptive device. Eur J Contracep Reprod Health Care 2003;8:122-125.

7. Markovitch O, Klein Z, Gidoni Y, Holzinger M, Beyth Y. Extrauterine mislocated IUD: is surgical removal mandatory? Contraception 2002;66:105-108.

8. Haimov-Kochman R, Amsalem H, Adoni Amiram, et al. Management of a perforated levonorgestrel-medicated intrauterine device: a pharmacokinetic study: case report. Human Reprod 2003;18:1231-1233.

9. Mirena (levonorgestrel-releasing intrauterine system) package insert. Wayne, N. J.: Bayer HealthCare; 2008. [En línea]. Dirección URL: .

10. Zazo FJ, Hernández RM. Relajación inducida por la progesterona en el cuello de vejiga urinaria del cerdo. Reduca 2011:3:41-42.

11. Xiao ZL, Pricolo V, Biancani P y Behar J. Role of progesterone signaling in the regulation of G-protein levels in female chronic constipation. Gastroenterology 2005;128:667-675.

12. Ozcelik B, Serin IS, Basbug M, Aygen E, Ekmekcioglu O. Differential diagnosis of intra-uterine device migrating to bladder using radiographic image of calculus formation and review of literature. Eur J Obstet Gynecol Reprod Biol 2003;108:94-96.

13. Balci O, Mahmoud AS, Capar M, Colakoglu MC. Diagnosis and management of intra-abdominal, mislocated intrauterine devices. Arch Gynecol Obstet 2010;281:1019-1022.

14. Turok DK, Gurtcheff SE, Gibson K, Handley E, Simonsen S, Murphy PA. Operative management of intrauterine device complications: a case series report. Contraception 2010;82:354-357.

15. Van Houdenhoven K, van Kaam KJ, van Grootheest AC, Salemans TH, Dunselman GA. Uterine perforation in women using a levonorgestrel-releasing intrauterine system. Contraception 2006;73:257-260.

16. García LB, Pichardo CM, Meza LM, Contreras CN. Manejo del dispositivo intrauterino traslocado. Rev Med Sur Mex 2012;19:7-9.